Zhengke Lian

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer

Juanjuan Feng, Zhongwei Hu, Xinting Xia et al. · Oncogene · 2023 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

Juanjuan Feng, Zhengke Lian, Xinting Xia et al. · Acta Pharmaceutica Sinica B · 2022 · 62 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer

Kun Li, Yanan Liu, Yi� Ding et al. · Journal of Clinical Investigation · 2022 · 36 citations · Full text

Medicine, Molecular Biology, Oncology +14

Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons

Yanan Liu, Longmiao Hu, Zhengzhen Wu et al. · Nature Communications · 2023 · 31 citations · Full text

Medicine, Immunology, Oncology +17

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers

Juanjuan Feng, Xuanzheng Xiao, Xinting Xia et al. · Cancer Cell · 2025 · 23 citations · Full text

Medicine, Oncology, Pharmacology +15